Evotec inks license agreement with J&J; Oncolytic virus biotech prices $15M IPO
Drug discovery and development player Evotec entered another licensing deal with Big Pharma — this time with J&J’s Janssen.
The companies put out
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
